Azitra, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $2.2M
- Price
- $0.1328
- % Change (Daily % change from the live per-ticker quote feed.)
- +4.81%
- Volume
- 2.0M
About
Azitra, Inc. is a pre-clinical biopharmaceutical company focused on developing precise treatments for various dermatological conditions. They innovate by utilizing engineered proteins and live biotherapeutic products to address skin diseases. The company's pipeline features several key therapeutic candidates: ATR-12: A genetically modified strain of S. epidermidis intended to treat Netherton syndrome, a specific skin disorder. ATR-04: Another modified S. epidermidis strain, designed to alleviate the papulopustular rash commonly experienced by cancer patients undergoing epidermal growth factor receptor inhibitor therapy. ATR-01: An engineered recombinant human filaggrin protein developed for the treatment of ichthyosis vulgaris, another dermatological ailment. Founded in 2014, Azitra, Inc. operates from its headquarters in Branford, Connecticut.
Quick stats
Shares outstanding16.2M
Computed float16.2M
Float / shares100.0%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001701478
Websitehttps://azitrainc.com
AI Summary
AI-generated1/17
minorbullishregulatory
Azitra, Inc. Regains Compliance with NYSE American Continued Listing Standards
Azitra received written notification from NYSE American confirming it has regained compliance with continued listing standards, specifically resolving deficiencies under Sections 1003(a)(ii) and 1003(a)(iii).
As a result, the "below compliance" indicator will be removed, and the company will no longer appear on the exchange's list of noncompliant issuers.
CEO Francisco Salva stated the company remains focused on advancing its ATR-COSF and ATR-04 programs following this resolution.